Haemonetics Acquires Vivasure Medical Limited
MWN-AI** Summary
Haemonetics Corporation, a prominent medical technology company, announced its acquisition of Vivasure Medical Limited, a Galway-based firm specializing in innovative percutaneous vessel closure technologies. The deal marks a significant enhancement in Haemonetics’ portfolio, particularly in the large-bore closure market, which is essential for structural heart and endovascular procedures.
Vivasure's flagship product, the PerQseal® Elite system, is designed to seal large-bore arteriotomies and venotomies with a unique bioabsorbable patch, providing a sutureless, fully absorbable solution. This technology received CE Mark approval for both arterial and venous use in Europe. Furthermore, positive clinical data from the ELITE arterial study demonstrated the product's ease of use and safety, reflecting no major complications at the 30-day follow-up.
The acquisition is structured with an upfront cash payment of €100 million and potential additional payments of €85 million based on sales growth and specific milestones. Haemonetics aims to leverage this acquisition to solidify its market presence and utilize its operational efficiencies to deliver increased value to healthcare providers.
Ken Crowley, Haemonetics' VP & General Manager, stated that adding Vivasure's technology enhances their closure device offerings and boosts their leadership position in advanced closure markets. Andrew Glass, CEO of Vivasure, expressed enthusiasm about the acquisition, highlighting that joining forces with Haemonetics would enable faster global distribution of the PerQseal Elite system, benefiting more patients and clinicians.
This strategic acquisition underlines Haemonetics' commitment to leveraging innovative solutions in healthcare, aligning with their broader mission to improve patient outcomes across various medical fields. The integration of Vivasure will potentially accelerate advancements in minimally invasive procedures, driving growth for Haemonetics in the coming years.
MWN-AI** Analysis
Haemonetics Corporation's acquisition of Vivasure Medical Limited represents a strategic move into the burgeoning market of minimally invasive surgical technologies. The transaction, valued at €100 million upfront, supplemented by potential contingent payments of up to €85 million, solidifies Haemonetics' position in the large-bore vessel closure segment. Given Vivasure's promising product, the PerQseal® Elite system, with clinical data indicating a 0% rate of major complications and quick hemostasis, this acquisition enhances Haemonetics' portfolio considerably.
Investors should view this acquisition as a potential catalyst for growth. The PerQseal Elite system has already received CE Mark approval and is positioned for U.S. FDA approval, which could significantly boost market adoption. The absence of major complications reported in clinical trials enhances the appeal of this device amongst medical professionals, and its sutureless design caters well to modern surgical trends that favor less invasive methods.
Moreover, the acquisition aligns with Haemonetics' strategy to expand its product offerings in the fast-growing structural heart and endovascular procedure markets. The integration of Vivasure's innovative technology is likely to benefit from Haemonetics' existing global distribution channels, allowing for expedited market penetration.
On the financial side, while the upfront investment is substantial, it is backed by cash reserves, reflecting prudent capital management. The contingent considerations linked to sales growth further indicate optimism regarding future performance, potentially validating the acquisition and driving share price appreciation.
However, investors should remain cautious of potential execution risks, including the challenges of integrating Vivasure's operations and achieving projected sales milestones. Regulatory hurdles for the U.S. market remain a possibility, which could impact timelines and revenue realization.
In summary, Haemonetics’ acquisition of Vivasure Medical Limited presents a compelling investment opportunity, with the potential for robust growth driven by innovative technologies and favorable market conditions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.
Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the PerQseal Elite arterial closure system and received CE Mark approval in Europe for both arterial and venous indications. Results from the prospective, single-arm, multi-center ELITE arterial study demonstrated ease of use with no need for pre-close, with 0% major complications at thirty-day follow-up, and immediate median time to hemostasis1.
The acquisition includes an upfront cash payment of €100 million, or approximately €52 million net of the value of certain previous investments and other loans made by Haemonetics to Vivasure as well as other customary closing adjustments, and up to an additional €85 million in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain prior investments and loan amounts. Haemonetics financed this transaction through available cash on hand.
"Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures," said Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics. "With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals."
"We're extremely proud of the progress made in advancing closure technology, and grateful to the clinicians, employees, board members, investors and government bodies who supported Vivasure's mission. Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide," said Andrew Glass, Chief Executive Officer of Vivasure Medical Limited.
About Haemonetics
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
About Vivasure Medical Limited
Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility.
PerQseal and PerQseal Elite are not available for sale in the United States. For more information, please visit www.vivasuremedical.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for the operation of Haemonetics, (ii) the anticipated benefits to Haemonetics arising from the completion of the acquisition, (iii) the impact of the acquisition on Haemonetics' business strategy and future business and operational performance, and (iv) the assumptions underlying or relating to any such statement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.
Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the failure to realize the anticipated benefits of the acquisition or the acquisition having an unanticipated impact; Haemonetics' ability to predict accurately the demand for products and products under development by it or Vivasure Medical Limited and to develop strategies to successfully address relevant markets; actual and anticipated achievement of the future sales growth and other milestones on which contingent consideration is based; the impact of competitive products and pricing; regulatory uncertainties, including in the receipt or timing of regulatory approvals; technical innovations that could render products marketed or under development by Haemonetics or Vivasure Medical Limited obsolete and risks related to the use and protection of intellectual property. These and other factors are identified and described in more detail in Haemonetics' filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.
1 In per-protocol population; Major Vascular Complications per VARC-3 definition
Investor Contacts: | |
Olga Guyette, VP-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Senior Director-Global Communications | |
(781) 356-9776 | |
SOURCE Haemonetics Corporation
FAQ**
How does the acquisition of Vivasure Medical Limited align with Haemonetics Corporation HAE's overall growth strategy in the medical technology market, particularly in the large-bore closure segment?
What are the projected financial impacts of the €100 million upfront cash payment and up to an additional €85 million in contingent consideration on Haemonetics Corporation HAE's balance sheet in the coming years?
What specific operational synergies does Haemonetics Corporation HAE anticipate leveraging from Vivasure Medical Limited's PerQseal Elite system to enhance market competitiveness and patient outcomes?
How will the successful acquisition and integration of Vivasure Medical Limited impact Haemonetics Corporation HAE's ability to address regulatory uncertainties regarding the PerQseal Elite's sales and distribution, especially in the U.S.?
**MWN-AI FAQ is based on asking OpenAI questions about Haemonetics Corporation (NYSE: HAE).
NASDAQ: HAE
HAE Trading
0.13% G/L:
$59.65 Last:
182,586 Volume:
$60.29 Open:
